COSCIENS Biopharma (TSE:CSCI)
TSX:CSCI
Total Valuation
COSCIENS Biopharma has a market cap or net worth of C$9.43M. The enterprise value is -C$23.31M.
Market CapC$9.43M
Enterprise Value-C$23.31M
Share Statistics
COSCIENS Biopharma has 3,184,159 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding3,184,159
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
COSCIENS Biopharma’s return on equity (ROE) is -0.20 and return on invested capital (ROIC) is -49.62%.
Return on Equity (ROE)-0.20
Return on Assets (ROA)-0.10
Return on Invested Capital (ROIC)-49.62%
Return on Capital Employed (ROCE)-0.55
Revenue Per Employee160.64K
Profits Per Employee-126.80K
Employee Count28
Asset Turnover―
Inventory Turnover―
Valuation Ratios
The current PE Ratio of COSCIENS Biopharma is ―. COSCIENS Biopharma’s PEG ratio is 0.00.
PE Ratio―
PS Ratio0.00
PB Ratio0.00
Price to Fair Value―
Price to FCF0.00
Price to Operating Cash Flow-0.59
PEG Ratio0.00
Income Statement
In the last 12 months, COSCIENS Biopharma had revenue of 4.50M and earned -3.55M in profits. Earnings per share was -1.92.
Revenue4.50M
Gross Profit4.28M
Operating Income-18.01M
Pretax Income-16.55M
Net Income-3.55M
EBITDA-17.99M
Earnings Per Share (EPS)-1.92
Cash Flow
In the last 12 months, operating cash flow was -14.44M and capital expenditures -176.00K, giving a free cash flow of -14.62M billion.
Operating Cash Flow-14.44M
Free Cash Flow-14.62M
Free Cash Flow per Share-4.59
Dividends & Yields
COSCIENS Biopharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.75
52-Week Price Change-34.66%
50-Day Moving Average2.73
200-Day Moving Average2.86
Relative Strength Index (RSI)54.20
Average Volume (3m)2.48K
Important Dates
COSCIENS Biopharma upcoming earnings date is Aug 13, 2026, After Close (Confirmed).
Last Earnings DateMay 12, 2026
Next Earnings DateAug 13, 2026
Ex-Dividend Date―
Financial Position
COSCIENS Biopharma as a current ratio of ―, with Debt / Equity ratio of 18.63%
Current Ratio―
Quick Ratio―
Debt to Market Cap―
Net Debt to EBITDA1.70
Interest Coverage Ratio―
Taxes
In the past 12 months, COSCIENS Biopharma has paid -1.47M in taxes.
Income Tax-1.47M
Effective Tax Rate―
Enterprise Valuation
COSCIENS Biopharma EV to EBITDA ratio is -1.07, with an EV/FCF ratio of -1.13.
EV to Sales4.29
EV to EBITDA-1.07
EV to Free Cash Flow-1.13
EV to Operating Cash Flow-1.13
Balance Sheet
COSCIENS Biopharma has C$27.80M in cash and marketable securities with C$1.69M in debt, giving a net cash position of C$26.12M billion.
Cash & Marketable SecuritiesC$27.80M
Total DebtC$1.69M
Net CashC$26.12M
Net Cash Per ShareC$8.20
Tangible Book Value Per Share―
Margins
Gross margin is 95.06%, with operating margin of ―, and net profit margin of ―.
Gross Margin95.06%
Operating Margin―
Pretax Margin―
Net Profit Margin―
EBITDA Margin―
EBIT Margin―
Analyst Forecast
The average price target for COSCIENS Biopharma is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-13.12%
EPS Growth Forecast60.90%